64 related articles for article (PubMed ID: 1615760)
21. [Long-term follow-up of 88 patients with Paget's disease treated by discontinuous courses of low-dose disodium etidronate].
Ravault A; Meunier PJ
Rev Rhum Mal Osteoartic; 1989 Mar; 56(4):293-302. PubMed ID: 2496461
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of sodium etidronate in the treatment of Paget's disease of bone. Osteitis deformans.
Stein I; Shapiro B; Ostrum B; Beller ML
Clin Orthop Relat Res; 1977; (122):347-58. PubMed ID: 402246
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog.
Michiels M; Monbaliu J; Hendriks R; Geerts R; Woestenborghs R; Heykants J
Arzneimittelforschung; 1987 Oct; 37(10):1159-67. PubMed ID: 3435588
[TBL] [Abstract][Full Text] [Related]
24. Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure.
Tang LY; Jee WS; Ke HZ; Kimmel DB
J Bone Miner Res; 1992 Sep; 7(9):1093-104. PubMed ID: 1414502
[TBL] [Abstract][Full Text] [Related]
25. The effect of long-term low-dose diphosphonate treatment on rat bone.
Evans RA; Howlett CR; Dunstan CR; Hills E
Clin Orthop Relat Res; 1982 May; (165):290-9. PubMed ID: 6210482
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.
Siefert HM; Maruhn D; Maul W; Förster D; Ritter W
Arzneimittelforschung; 1986 Oct; 36(10):1496-502. PubMed ID: 3814211
[TBL] [Abstract][Full Text] [Related]
27. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
29. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
30. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
32. [Bone histomorphometric study in involuted fractured osteoporosis treated with 1-ethane-1-hydroxybiphosphonate (etidronate) during one year].
Pallot-Prades B; Chappard D; Tavan P; Prallet B; Riffat G; Alexandre C
Rev Rhum Mal Osteoartic; 1991 Nov; 58(11):771-6. PubMed ID: 1780652
[TBL] [Abstract][Full Text] [Related]
33. Effect of a diphosphonate on the osteoinductive activity of rat bone matrix.
Bauer FC; Nilsson OS; Tornkvist H; Lindholm TC; Lindholm TS
Clin Orthop Relat Res; 1984 May; (185):266-9. PubMed ID: 6423335
[TBL] [Abstract][Full Text] [Related]
34. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
35. Effects of propane-2, 2-diphosphonate (PDP) on matrix-induced ectopic bone formation in comparison to ethane-1-hydroxy-1, 1-diphosphonate (EHDP).
Rüther W; Kindermann D; Gebhardt M; Münzenberg KJ
Clin Orthop Relat Res; 1990 Sep; (258):122-34. PubMed ID: 2118435
[TBL] [Abstract][Full Text] [Related]
36. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
Mallette LE; LeBlanc AD; Pool JL; Mechanick JI
J Bone Miner Res; 1989 Apr; 4(2):143-8. PubMed ID: 2499164
[TBL] [Abstract][Full Text] [Related]
37. The long-term skeletal effects of EHDP in dogs.
Flora L; Hassing GS; Cloyd GG; Bevan JA; Parfitt AM; Villanueva AR
Metab Bone Dis Relat Res; 1981; 3(4-5):289-300. PubMed ID: 6820110
[TBL] [Abstract][Full Text] [Related]
38. Long term retention of 237Np in rats.
Wirth R; Volf V
Int J Radiat Biol Relat Stud Phys Chem Med; 1984 Dec; 46(6):787-92. PubMed ID: 6335500
[TBL] [Abstract][Full Text] [Related]
39. Dog Days.
Dus G
Science; 1959 Jul; 130(3368):131. PubMed ID: 17812361
[No Abstract] [Full Text] [Related]
40. Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective.
Vergara-Hernandez FB; Nielsen BD; Colbath AC
Animals (Basel); 2022 Jul; 12(13):. PubMed ID: 35804621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
